West Pharmaceutical Services, Inc. logo

West Pharmaceutical Services, Inc. (WST)

Market Open
24 Feb, 20:10
NYSE NYSE
$
245. 67
+1.45
+0.59%
$
17.37B Market Cap
49.01 P/E Ratio
0.8% Div Yield
312,547 Volume
7.62 Eps
$ 244.22
Previous Close
Day Range
241.58 248.54
Year Range
187.43 322.34
Want to track WST and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
WST earnings report is expected in 57 days (22 Apr 2026)
WST Launches Synchrony S1 Prefillable Syringe at Pharmapack

WST Launches Synchrony S1 Prefillable Syringe at Pharmapack

West Pharmaceutical debuts the Synchrony S1 prefillable syringe at Pharmapack 2026, enhancing biologics, vaccines and home-care support.

Zacks | 1 month ago
All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy

All You Need to Know About West Pharmaceutical (WST) Rating Upgrade to Strong Buy

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 1 month ago
After Plunging 9.7% in 4 Weeks, Here's Why the Trend Might Reverse for West Pharmaceutical (WST)

After Plunging 9.7% in 4 Weeks, Here's Why the Trend Might Reverse for West Pharmaceutical (WST)

The heavy selling pressure might have exhausted for West Pharmaceutical (WST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks | 1 month ago
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

Reasons to Add West Pharmaceutical Stock to Your Portfolio Now

WST is riding on surging GLP-1 demand and HVP expansion. Yet, pricing pressure, tariff risks and contract manufacturing headwinds cloud the near-term outlook.

Zacks | 1 month ago
Wall Street Analysts See a 26.42% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?

Wall Street Analysts See a 26.42% Upside in West Pharmaceutical (WST): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks | 1 month ago
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now

Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now

WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.

Zacks | 2 months ago
West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Seekingalpha | 2 months ago
West Pharmaceutical: Back To Growth

West Pharmaceutical: Back To Growth

West Pharmaceutical Services is rated a buy, supported by strong Q3 results, raised guidance, and a resilient long-term growth thesis. WST's focus on high-value proprietary elastomer components and secular industry drivers, like GLP-1 demand, underpins robust margin and revenue growth. Risks include questionable capital allocation, recent insider selling during buybacks, and potential disruption from oral drug alternatives.

Seekingalpha | 2 months ago
West Pharmaceutical Services, Inc. (WST) Presents at Stephens Annual Investment Conference 2025 Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Stephens Annual Investment Conference 2025 Transcript

West Pharmaceutical Services, Inc. ( WST ) Stephens Annual Investment Conference 2025 November 20, 2025 12:00 PM EST Company Participants Robert McMahon - Senior VP & CFO Shane Campbell - SVP & Chief Proprietary Segment Officer John Sweeney - Head of Investor Relations Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division Welcome to day 3 of Stephens 2025 Investment Conference here at Nashville. I'm Mac Etoch, the Life Science Tools and Pharma Services Analyst.

Seekingalpha | 3 months ago
West Pharmaceutical Services, Inc. (WST) Presents at Jefferies London Healthcare Conference 2025 Transcript

West Pharmaceutical Services, Inc. (WST) Presents at Jefferies London Healthcare Conference 2025 Transcript

West Pharmaceutical Services, Inc. ( WST ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Robert McMahon - Senior VP & CFO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research.

Seekingalpha | 3 months ago
West Pharmaceutical Services, Inc. (WST) Presents at UBS Global Healthcare Conference 2025 Transcript

West Pharmaceutical Services, Inc. (WST) Presents at UBS Global Healthcare Conference 2025 Transcript

West Pharmaceutical Services, Inc. ( WST ) UBS Global Healthcare Conference 2025 November 11, 2025 9:30 AM EST Company Participants Robert McMahon - Senior VP & CFO Presentation Unknown Analyst Joining our next session is with West Pharma and joining me on stage from West is Bob McMahon. Well, Bob.

Seekingalpha | 3 months ago
WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit

WST Stock Up on Q3 Earnings Beat, EPS View Raised on Demand & FX Benefit

West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.

Zacks | 4 months ago
Loading...
Load More